Sanofi bets on Sino Biopharm's transplant drug in $1.5bn licensing deal [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Sanofi has taken a chance on Sino Biopharmaceutical's first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up to $1.53bn. As part of this deal, Sanofi will pay $135m upfront for the global development, manufacturing and commercialisation rights to Sino's novel Janus kinase (JAK)/Rho-associated protein kinase (ROCK) inhibitor pill, rovadicitinib, which was developed by Sino's subsidiary, Chia Tai Tianqing Pharmaceutical Group. This agreement also sees Sanofi commit up to $1.39bn towards potential development, regulatory and sales-based milestone payments – taking the total value up to $1.53bn. The Hong Kong-based pharma is also eligible to receive up to double-digit tiered royalties on the drug's annual net sales. Rovadicitinib is currently marketed in China under the brand name Anxu. The drug originally gained approval for the frontline treatment of three types of rare bone marrow cancer, myelofibrosis, in February 2026.
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities [Yahoo! Finance]Yahoo! Finance
- Podcast: Sanofi's head of clinical supply chain operations on evolving the clinical trial supply model [Yahoo! Finance]Yahoo! Finance
- Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent directorGlobeNewswire
SNY
Sec Filings
- 3/4/26 - Form 6-K
- 3/3/26 - Form 6-K
- 2/23/26 - Form 6-K
- SNY's page on the SEC website